Table 3

Relative changes (fold-change) in the transcription of those genes that were significantly modulated by anti-tumour necrosis factor α (anti-TNFα) treatment in non-responders

Gene symbolActive CD without anti-TNF versus non-IBD controlsActive CD with anti-TNF (non-responders) versus non-IBD controlsInactive CD with anti-TNF (responders) versus non-IBD controls
IL65.151.40−1.02
PMAIP14.001.241.23
TNFAIP33.881.481.37
CD693.851.071.06
SLC2A33.831.421.09
GPR1833.471.351.02
MMP93.121.311.29
CD832.831.021.01
VCAM12.821.311.26
PLAU2.781.331.01
NFKBIA2.471.171.10
LAMB12.451.301.48
ETS22.401.451.44
CH25H2.271.37−1.02
AHR2.271.301.26
HSPA132.261.471.43
TNFAIP82.241.381.03
CHSY12.221.401.19
AMOTL22.171.241.32
MCL12.151.311.34
PANX12.081.271.16
GPR372.081.191.13
OSBPL82.071.191.26
PXDN2.041.221.15
ATP10D2.031.331.16
OTUD11.96−1.141.22
ARL4C1.951.161.13
GADD45B1.931.051.11
LOC1005069351.901.021.02
CCPG11.891.141.24
PELI11.861.231.18
MNT1.841.131.17
NID11.811.171.09
KLF101.69−1.111.01
TLR41.571.041.05
PRNP1.571.04−1.02
NFIL31.54−1.13−1.11
MTMR11−2.12−1.41−1.32
  • CD, Crohn's disease; Non-IBD; non-inflammatory bowel disease; anti-TNF, anti-tumour necrosis factor.